Edition:
United States

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

163.10USD
4:00pm EDT
Change (% chg)

$3.83 (+2.40%)
Prev Close
$159.27
Open
$158.95
Day's High
$165.00
Day's Low
$158.95
Volume
105,138
Avg. Vol
145,652
52-wk High
$208.78
52-wk Low
$71.45

Select another date:

Wed, Sep 5 2018

Photo

Bayer open for drug licensing deals, cutting debt remains priority

FRANKFURT Bayer is ready to spend money on more drug licensing agreements like last year's deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.

Bayer open for drug licensing deals, cutting debt remains priority

FRANKFURT, Sept 5 Bayer is ready to spend money on more drug licensing agreements like last year's deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.

Loxo-Bayer cancer drug gets priority review from FDA

Loxo Oncology and Bayer AG said on Tuesday the U.S. Food and Drug Administration granted priority review to their cancer drug and would decide on the marketing application by Nov. 26.

Loxo-Bayer cancer drug gets priority review from FDA

May 29 Loxo Oncology and Bayer AG said on Tuesday the U.S. Food and Drug Administration granted priority review to their cancer drug and would decide on the marketing application by Nov. 26.

Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

CORRECTED-UPDATE 1-Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO, May 16 An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO, May 16 An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

BRIEF-Loxo Oncology Reports Qtrly Loss Per Share Of $0.12

* LOXO ONCOLOGY - AS OF MARCH 31, 2018, CO HAD AGGREGATE CASH, CASH EQUIVALENTS AND INVESTMENTS OF $735.6 MILLION, COMPARED TO $626.2 MILLION AS OF DEC 31, 2017

BRIEF-Veracyte Announces Precision Medicine Collaboration With Loxo Oncology

* VERACYTE ANNOUNCES PRECISION MEDICINE COLLABORATION WITH LOXO ONCOLOGY

Loxo, Illumina to partner for diagnostic tool targeting cancer

Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

Select another date: